Extrapulmonary small-cell carcinoma compared with small-cell lung carcinoma - A retrospective single-center study

dc.authoridCicin, Irfan/0000-0002-7584-3868;
dc.authorwosidUygun, Kazim/AFL-7917-2022
dc.authorwosidKocak, Zafer/AEG-7828-2022
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.authorwosidUygun, Kazim/AAG-7880-2022
dc.contributor.authorCicin, Irfan
dc.contributor.authorKaragol, Hakan
dc.contributor.authorUzunoglu, Sernaz
dc.contributor.authorUygun, Kazim
dc.contributor.authorUsta, Ufuk
dc.contributor.authorKocak, Zafer
dc.contributor.authorCaloglu, Murat
dc.date.accessioned2024-06-12T11:01:40Z
dc.date.available2024-06-12T11:01:40Z
dc.date.issued2007
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBACKGROUND. The study was conducted with the aim of reviewing the clinical features, therapy, and natural course of patients with extrapulmonary small-cell carcinoma (EPSCC) and small-cell lung carcinoma (SCLC) to better define current concepts regarding EPSCCs. METHODS. The medical records of patients with proven diagnosis of small-cell carcinoma (SmCQ between January 1999 and May 2006 were retrospectively reviewed. A total of 65 SmCC cases were included in the study (11 [17%] cases of EPSCC and 54 [83%] cases of SCLQ. RESULTS. Progression-free survival of all patients with EPSCC and patients with-extensive EPSCC disease was 7 months (95% confidence interval 10], 0.58-13.42) and 7 months (95% Cl, 4.71-13.29), respectively. Overall survival of all patients with EPSCC and patients with extensive EPSSC disease was 32 months (95% CI, 18.74-45.26) and 28 months (95% Cl, 12.24-43.76), respectively. Progression-free survival and overall survival for all patients with SCLC were 5 months (95% Cl, 2.26-7.74) and 10 months (95% Cl, 5.95-14.05), respectively. Progression-free survival and overall survival for patients with extensive disease were 3 months (95% Cl, 4.71-13.29) and 5 months (95% CI, 3.33-6.67), respectively. Overall survival was significantly better in all patients with EPSCC and in patients with extensive EPSCC disease compared with A patients with SCLC and patients with extensive SCLC disease (P =.014, P -.004, respectively). Early death and brain metastasis were observed in a higher number of patients with SCLC compared with EPSCC) however, these results were not statistically significant (P 33 and P =.076, respectively). Smoking history was significantly less in the FPSCC group (P <.0001). CONCLUSIONS. EPSCC is usually treated similarly to SCLC. However, this study suggests some differences such as etiology, clinic course, survival, frequency of brain metastases, and early death between these entities. These possible differences may influence the choice of therapeutic approach. Cancer 2007; 110: 106&76. (c) 200 7 American Cancer Society.en_US
dc.identifier.doi10.1002/cncr.22887
dc.identifier.endpage1076en_US
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.issue5en_US
dc.identifier.pmid17614337en_US
dc.identifier.scopus2-s2.0-34548145113en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1068en_US
dc.identifier.urihttps://doi.org/10.1002/cncr.22887
dc.identifier.urihttps://hdl.handle.net/20.500.14551/20987
dc.identifier.volume110en_US
dc.identifier.wosWOS:000249191100018en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofCanceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectExtrapulmonary Small-Cell Carcinomaen_US
dc.subjectPulmonary Small-Cell Carcinomaen_US
dc.subjectTreatmenten_US
dc.subjectPrognosisen_US
dc.subjectTherapyen_US
dc.subjectCanceren_US
dc.subjectChemotherapyen_US
dc.titleExtrapulmonary small-cell carcinoma compared with small-cell lung carcinoma - A retrospective single-center studyen_US
dc.typeArticleen_US

Dosyalar